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Background: Because of the absorption of glucose in peritoneal dialysis (PD) solution, PD patients show an
atherogenic lipid profile, which is predictive of poor survival in PD patients. Lipoprotein subclasses consist of a
continuous spectrum of particles of different sizes and densities (fraction). In this study, we investigated the
lipoprotein fractions in PD patients with controlled serum low-density lipoprotein (LDL) cholesterol level, and
evaluated the effects of icodextrin on lipid metabolism.
Methods: Forty-nine PD patients were enrolled in this cross-sectional study in Japan. The proportions of cholesterol
levels to total cholesterol level (cholesterol proportion) in 20 lipoprotein fractions were measured using an
improved method of high-performance gel permeation chromatography (HPGPC).
Results: Twenty-six patients used icodextrin. Although no significant differences in cholesterol levels in LDL and
high-density lipoprotein (HDL) were observed between the patients using icodextrin (icodextrin group) and control
groups, HPGPC showed that the icodextrin group had significantly lower cholesterol proportions in the small LDL
(t-test, p=0.053) and very small LDL (p=0.019), and significantly higher cholesterol proportions in the very large HDL
and large HDL than the control group (p=0.037; p=0.066, respectively). Multivariate analysis adjusted for patient
characteristics and statin use showed that icodextrin use was negatively associated with the cholesterol proportions
in the small LDL (p=0.037) and very small LDL (p=0.026), and positively with those in the very large HDL (p=0.040),
large HDL (p=0.047), and medium HDL (p=0.009).
Conclusions: HPGPC showed the relationship between icodextrin use and the cholesterol proportions in
lipoprotein fractions in PD patients. These results suggest that icodextrin may improve atherogenic lipid profiles in
a manner different from statin.
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Cardiovascular disease (CVD) is one of the leading causes
of death in patients on peritoneal dialysis (PD) [1,2]. One
of the risk factors of CVD is dyslipidemia. The kidney dis-
ease outcomes quality initiative (K/DOQI) reported that
78.6% of PD patients need treatment for dyslipidemia [3].
Lipoprotein subfractions consist of a continuous
spectrum of particles of different sizes and densities.
Small dense low-density lipoproteins (LDLs) and high-
density lipoproteins (HDLs) are related to CVD events
[4,5]. PD patients tend to show high levels of total chol-
esterol, LDL cholesterol (LDL-C), triglyceride (TG), and
small dense LDL-C with a low level of HDL cholesterol
(HDL-C) [6].
Icodextrin is a starch-derived, branched, water-soluble
glucose polymer, a colloid osmotic agent, and derived
from maltodextrin. It is used in the form of an aqueous
solution for PD. The effect of icodextrin on cholesterol
level has not been established yet. According to some re-
ports, icodextrin does not change total cholesterol level
[7,8]. On the other hand, there are reports that icodex-
trin increases HDL-C level and decreases LDL-C and
TG levels [9,10], and there is a report that icodextrin de-
creases small dense LDL levels [11]. TG level is reduced
by icodextrin [9,10,12]. However, the effect of icodextrin
on lipoprotein subclasses has not been fully clarified yet.
The typical lipid profile of PD patients is atherogenic.
However, there has been no clinical trial that determines
whether all PD patients with dyslipidemia should receive
lipid treatment for the prevention of CVD. It is import-
ant to study in the detail the lipoprotein subclasses in
PD patients to prevent the occurrence of CVD in these
patients. We previously established a method of high-
performance gel permeation chromatography (HPGPC),
which can separate lipoproteins into 20 fractions, and
reported that small LDL-C and very small LDL-C levels
positively correlate with visceral fat area [13,14]. There-
fore, the aim of this study is to investigate the lipid pro-
files at subclass levels in PD patients and evaluate the
relationship between icodextrin and lipid profiles, par-
ticularly cholesterol levels, by HPGPC.
Methods
Study design and study population
This is a cross-sectional study of PD patients (more than
20 years old) treated at Tokyo Kyosai Hospital, Tokyo,
Japan, and JA Toride Medical Center, Ibaraki, Japan, which
was approved by the local ethics committees of Tokyo
Kyosai Hospital and JA Toride Medical Center. The inves-
tigation was carried out at a time from October 2011 to
December 2011 at outpatient clinic. Written informed
consent was obtained from each patient. Patients were
eligible for inclusion in this study if they were able to sta-
bly continue continuous ambulatory PD (37 patients) orautomated PD (12 patients) as outpatients. They were
treated with PD solutions containing dextrose (Dianeal-
NPD-2, -NPD-4 1.5 or 2.5, Baxter Japan, Tokyo; Mid Peric
or Mid Peric L 135 or 250, Terumo, Tokyo) and with or
without a PD solution containing icodextrin (Extraneal,
Baxter Japan, Tokyo). All the patients in this study who se-
lected Baxter’s PD system had used a PD solution contain-
ing icodextrin since the start of their PD. Because of
Japanese national health insurance restrictions, they used
only one bag of icodextrin, 1.5 to 2 L, for 8 to 12 hours
per day. We adhered to the Japanese Society for Dialysis
Therapy guidelines for PD [15]. Dyslipidemia was diag-
nosed on the basis of the criteria of the Japan Athero-
sclerosis Society [16]. A high LDL-C level was treated in
accordance with the evidence-based practice guideline
2009 for the treatment of chronic kidney disease estab-
lished by the Japanese Society of Nephrology and clin-
ical guidelines for the evaluation and treatment of
cardiovascular complications in hemodialysis patients
established by the Japanese Society for Dialysis Therapy
[17,18]. Serum LDL-C level was maintained at less than
120 mg/dl by administration of statin. Statins were ad-
ministered to 16 patients (pravastatin, 4 patients; ator-
vastatin, 4; rosuvastatin, 6; pitavastatin, 2). None of the
patients was administered ezetimibe or fibrates. We ex-
cluded patients who had malignant diseases, infectious
diseases, or severe liver diseases.
Data
Patient demographics including age, gender, and history
of diabetes mellitus (DM) as well as comorbid condi-
tions were obtained from the medical records of the pa-
tients at each hospital. Blood samples were obtained
from every patient after a 12 hour overnight fasting with
an overnight dwell of PD solution containing 2.5% dex-
trose. Serum samples were dispensed into three tubes,
one for routine serum biochemistry at each hospital, one
for measurement of apolipoprotein B at SRL Inc., Tokyo,
Japan, and one for HPGPC at Skylight Biotech Inc.,
Akita, Japan. The blood samples for HPGPC were frozen
at -80°C immediately after their collection until use. Rou-
tine serum biochemistry was carried out by standard
methods at each hospital. Apolipoprotein B was measured
using an immunoassay kit (Apolipoprotein B; Sekisui
Medical Co., Tokyo, Japan). Lipoprotein fractions were an-
alyzed by HPGPC as previously described [13,14]. In brief,
4 μL of whole serum samples were injected into columns
and continuously monitored at 550 nm after an online en-
zymatic reaction. The HPGPC is used to simultaneously
monitor and obtain simultaneously cholesterol and trigly-
ceride levels in lipoprotein fractions in a single injection of
samples. In this study, only cholesterol levels in lipopro-
tein fractions were analyzed by a mathematical proced-
ure with modified Gaussian curve fitting to resolve
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and F2], very-low-density lipoprotein (VLDL) (F3 - F7),
LDL (F8 - F13), and HDL (F14 - F20) (Table 1). The pro-
portion of cholesterol level in each lipoprotein fraction to
total cholesterol level (cholesterol proportion) was calcu-
lated using the following formula: Cholesterol proportion =
cholesterol level in each lipoprotein fraction (mg/dl)/total
cholesterol level (mg/dl). Although the classification of
LDLs based on HPGPC is not the same as that based on
nondenaturing gradient gel electrophoretic analysis by
Austin et al, medium, small, and very small LDLs (F9 -
F13) are consistent with the classification of small dense
LDLs by Austin et al. [13,14,19].
Statistical analyses
Results are presented as mean±standard deviation (SD).
Intergroup comparisons were performed using a chi-
square test for categorical variables and the t-test for con-
tinuous variables. Univariate linear regression analysis was
carried out to determine the relationships between total
cholesterol level and clinical and biochemical characteris-
tics of patients. Multivariate linear regression analysis was
used to determine whether icodextrin use is independently
associated with the cholesterol proportion level in each









LDL Large LDL F8
Medium LDL F9
Small LDL F10
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F12
F13





Very small HDL F19
F20
Abbreviations: CM chylomicron, VLDL very-low-density lipoprotein, LDL
low-density lipoprotein, HDL high-density lipoprotein.DM, statin use, and total cholesterol level, and a factor
that was previously selected in the univariate linear regres-
sion analysis. These analyses were conducted using SAS,
version 9.2 (SAS, Inc., North Carolina, US). Statistical sig-
nificance was defined as p<0.05.Results
Patient characteristics
Forty-nine patients on PD were included as samples for
analysis. Twenty-six patients used icodextrin (icodextrin
group), and twenty-three patients did not (control group).
Patient demographics including biochemical data are
shown in Table 2. The causes of end-stage kidney disease
were as follows: diabetic nephropathy in 21 patients,
chronic glomerulonephritis in 16, IgA nephropathy in 4,
nephrosclerosis in 4, and unknown in 4.
The icodextrin and control groups were matached for
gender, age, BMI, serum calcium level, serum albumin
level, C-reactive protein (CRP) level, and PD vintage.
The dialysate/plasma creatinine ratio (D/P Cr) of the
icodextrin group was higher than that of the control
group. Although no statistically significant difference
was found, more patients with DM were included in the
icodextrin group. Marginally more patients with dyslip-
idemia were in the control group than in the icodextrin
group (p=0.06). No statistically significant difference in
statin use was observed.Table 2 Clinical and biochemical characteristics of
patients in this study
All Control Icodextrin p
N (%) 49 23 (46.9) 26 (53.1)
Male (%) 38 (77.6) 19 (82.6) 19 (73.1) 0.51
Age 64.1±11.8 64.9±12.5 63.5±11.4 0.69
Height (cm) 160.9±9.9 159.9±10.1 161.8±9.8 0.50
Weight (kg) 60.6±11.9 57.2±11.2 63.6±11.9 0.06
BMI 23.3±3.7 22.3±3.6 24.2±3.5 0.07
DM (%) 21 (42.8) 7 (30.4) 14 (53.8) 0.15
Dyslipidemia (%) 34 (69.4) 19 (82.6) 15 (57.7) 0.06
Statin use (%) 16 (32.6) 8 (34.8) 8 (30.8) 0.77
Creatinine (mg/dl) 10.3±3.4 10.0±3.5 10.6±3.3 0.48
Albumin (g/dl) 3.3±0.5 3.4±0.5 3.2±0.4 0.20
CRP (mg/dl) 0.41±1.0 0.45±1.3 0.38±0.6 0.80
Glucose (mg/dl) 116.1±30.6 109.4±24.2 122.2±34.8 0.15
PD vintage (months) 39.9±28.5 42.1±30.5 37.9±27.1 0.61
D/P Cr 0.63±0.13 0.56±0.13 0.68±0.11 0.002
Values are expressed as mean ± standard deviation. The values are compared
between the groups by the chi-square test or t-test.
Abbreviations: control control group, icodextrin icodextrin group, BMI body
mass index, DM diabetes mellitus, CRP C-reactive protein, PD peritoneal
dialysis, D/P Cr dialysate/plasma creatinine ratio.
Figure 1 Representative chromatographic pattern obtained by
high-performance gel permeation chromatography. The
chromatography system could detect the cholesterol (red line) and
triglyceride (blue line) levels in lipoprotein fractions from a diabetic
male patient using icodextrin with a total cholesterol level of 175
mg/dl and a total triglyceride level of 53 mg/dl. In this study, the
cholesterol levels in lipoprotein fractions were analyzed. Arrow 1
indicates the peaks for VLDL and LDL; arrow 2, HDL; arrow 3,
endogenous free glycerol. Abbreviations: VLDL, very-low-density
lipoprotein; LDL, low-density lipoprotein; HDL,
high-density lipoproteins.
Kanda et al. BMC Nephrology 2013, 14:234 Page 4 of 8
http://www.biomedcentral.com/1471-2369/14/234Cholesterol and TG levels in lipoproteins
Serum samples from patients analyzed by HPGPC showed
two separate peaks in the cholesterol profile and three
peaks in the triglyceride profile. The first peak eluted at
about 20–24 min contained VLDL and LDL and the sec-
ond peak eluted at 24–27 min contained HDL (Figure 1).
The third peak eluted at 30–31 min in the triglyceride
profile showed endogenous free glycerol (Figure 1).
The differences in cholesterol level in lipoprotein clas-
ses and TG level were examined between the icodextrin
and control groups (Table 3). No statistically significant
differences in cholesterol and TG levels in lipoprotein
classes were observed between the icodextrin and con-
trol groups (Table 3). The apolipoprotein B level in the
icodextrin group was lower than that in the control
group; this difference, however, did not reach statistical
significance.Table 3 Cholesterol levels in lipoproteins and TG levels
All
Total cholesterol level (mg/dl) 183.1±37.2
CM cholesterol level (mg/dl) 1.1±1.8
VLDL-C level (mg/dl) 37.6±16.0
LDL-C level (mg/dl) 93.7±27.6
HDL-C level (mg/dl) 50.8±20.3
Triglyceride level (mg/dl) 139.3±70.6
Apolipoprotein B level (mg/dl) 91.6±24.3
Values are expressed as mean ± standard deviation. The values are compared betw
Abbreviations: control control group, icodextrin icodextrin group, CM chylomicron, VL
cholesterol, HDL-C high-density lipoprotein cholesterol.The cholesterol proportion in each lipoprotein fraction
is shown in Figure 2 and Table 4. In small LDL (F10)
and very small LDL (F11), the cholesterol proportions in
the icodextrin group were lower than those in the con-
trol group (F10, p=0.053; F11, p=0.019). In very large
HDL (F15), and large HDL (F16), the cholesterol propor-
tions in the icodextrin group were higher than those in
the control group (F15, p=0.037; F16, p=0.066).
Independent effect of icodextrin on cholesterol
proportions in lipoproteins
A single regression analysis showed that gender was
associated with total cholesterol level (p=0.0035). Age;
BMI; serum creatinine, albumin, and plasma glucose
levels; PD vintage; and D/P Cr were not associated with
total cholesterol level. Multivariate regression analysis
adjusted for gender, BMI, total cholesterol level, DM,
and statin use showed that icodextrin use was independ-
ently associated with cholesterol proportions (Table 5).
In small LDL (F10) and very small LDL (F11), the chol-
esterol proportions were negatively associated with ico-
dextrin use. In very large HDL (F15), large HDL (F16)
and medium HDL (F17), the cholesterol proportions
were positively associated with icodextrin use.
Discussion
In this study, we were able to evaluate in detail the lipo-
protein profile among PD patients with controlled serum
LDL levels. Although no significant differences were ob-
served in patient characteristics and cholesterol levels in
LDL and HDL between the icodextrin and control
groups, the icodextrin group showed significantly lower
cholesterol proportions in small and very small LDLs,
and significantly higher cholesterol proportions in very
large and large HDLs. This study was partially consistent
with previous reports that there are no significant differ-
ences in total cholesterol and TG levels between the ico-
dextrin and control groups [7,8]. However, there has
been no report on the details of the effects of icodextrin








een the groups by the chi-square test or t-test.
DL-C very-low-density lipoprotein cholesterol, LDL-C low-density lipoprotein
Figure 2 Cholesterol proportions in each lipoprotein fractions
in icodextrin group compared with those in control group. The
average cholesterol proportion in each lipoprotein fraction is
indicated in the graph. The values are compared between the
groups by the t-test. *, p<0.05. Abbreviations: proportion, average of
the proportion of cholesterol level in each lipoprotein fraction to
total cholesterol level; control, control group; icodextrin, icodextrin
group; F1-20, Fraction 1-20.
Table 4 Cholesterol proportions in lipoprotein fractions in ico
Class Subclass Fraction ALL
CM F1 0.0036±0.00
F2 0.0025±0.00
VLDL Large VLDL F3 0.0095±0.01
F4 0.02±0.019
F5 0.064±0.026
Medium VLDL F6 0.065±0.023
Small VLDL F7 0.046±0.012
LDL Large LDL F8 0.14±0.033
Medium LDL F9 0.21±0.041
Small LDL F10 0.11±0.027
Very small LDL F11 0.038±0.009
F12 0.0045±0.00
F13 0.0064±0.00
HDL Very large HDL F14 0.0025±0.00
F15 0.018±0.018
Large HDL F16 0.079±0.057
Medium HDL F17 0.083±0.028
Small HDL F18 0.068±0.017
Very small HDL F19 0.025±0.005
F20 0.007±0.001
Values are expressed as mean ± standard deviation. The values are compared betw
Abbreviations: icodextrin icodextrin use, statin stain use, CM chylomicron, VLDL very-
lipoprotein, cholesterol proportion proportion of cholesterol level in each lipoprotein
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and control groups. These findings suggest a possibility
that icodextrin may affect the lipid profiles at the fraction
level in PD patients with controlled serum LDL levels.
In this study, we showed the relationship between
icodextrin use and decreased cholesterol proportions in
small LDL (F10) and very small LDL (F11). Our results
suggest that icodextrin may be effective for reducing
cholesterol levels in small and very small LDLs via a
mechanism different from that for statins. TG level ex-
erts a strong influence on LDL size [20]. Icodextrin has
been reported to decrease TG level with decreased glu-
cose absorption level in PD patients [9]. These reports
suggest that icodextrin may decrease small LDL and very
small LDL levels by decreasing TG level. Moreover, it
has been reported that insulin resistance is associated
with excess hepatic production of large VLDLs [21].
Large VLDLs are precursors of small dense LDLs [22].
Using icodextrin lowers insulin level and improves insu-
lin resistance [23,24]. Therefore, it is suggested that
there is another mechanism by which icodextrin de-
creases small LDL and very small LDL levels, that is, by
improving insulin resistance.
Dyslipidemia is a risk factor for CVD in CKD patients.
Statins are considered effective for treating dyslipidemiadextrin group compared with those in control group
Control Icodextrin p
75 0.0045±0.01 0.0029±0.0036 0.47









1 0.042±0.0069 0.035±0.0099 0.019*
34 0.0045±0.0033 0.0044±0.0035 0.93
11 0.0063±0.00092 0.0064±0.0013 0.82





9 0.026±0.0059 0.024±0.0059 0.36
4 0.0069±0.0013 0.0071±0.0015 0.6
een the groups by the t-test. *, p<0.05.
low-density lipoprotein, LDL low-density lipoprotein, HDL high-density
fraction to total cholesterol level.
Table 5 Icodextrin use correlated with cholesterol
proportions in lipoprotein fractions
Icodextrin
Class Subclass Fraction β p
CM F1 −0.0026 (0.0027) 0.35
F2 −0.0011 (0.0015) 0.47
VLDL Large VLDL F3 −0.0033 (0.0030) 0.27
F4 −0.0063 (0.0055) 0.26
F5 −0.0077 (0.0075) 0.31
Medium VLDL F6 −0.0094 (0.0071) 0.19
Small VLDL F7 −0.0023 (0.0039) 0.55
LDL Large LDL F8 −0.00057 (0.0096) 0.95
Medium LDL F9 −0.014 (0.012) 0.25
Small LDL F10 −0.017 (0.0079) 0.037*
Very small LDL F11 −0.0061 (0.0027) 0.026*
F12 −0.00083 (0.00089) 0.36
F13 0.00011 (0.00035) 0.76
HDL Very large HDL F14 0.00075 (0.00043) 0.087
F15 0.012 (0.0055) 0.040*
Large HDL F16 0.036 (0.017) 0.047*
Medium HDL F17 0.020 (0.0075) 0.009*
Small HDL F18 0.0033 (0.0044) 0.45
Very small HDL F19 −0.00016 (0.0015) 0.92
F20 0.00047 (0.00037) 0.20
Values are expressed as estimated parameter (standard error) and p values.
The variables in multivariate linear regression analysis include gender, body
mass index, DM, total cholesterol level, statin use, and icodextrin use. *, p<0.05
Abbreviations: icodextrin icodextrin use, β estimated parameter; CM
chylomicron, VLDL very-low-density lipoprotein, LDL low-density lipoprotein,
HDL high-density lipoprotein, cholesterol proportion, proportion of cholesterol
level in each lipoprotein fraction to total cholesterol level; DM
diabetes mellitus.
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studies of dialysis patients did not show the efficacy of
statins in reducing the number of cardiovascular events
[26-28]. A meta-analysis showed that statins had little ef-
fect on all-cause mortality, cardiovascular mortality, or
cardiovascular events in dialysis patients [29]. Although
the above research results suggest that lipid-lowering
therapies are not effective in preventing the development
of CVD in dialysis patients, their benefit should not
completely be denied. There are various risk factors that
contribute to CVD in PD patients, not only traditional
risk factors, but also dyslipidemia, inflammation, homo-
cysteine, and vascular calcification [30-32]. Because these
factors are associated with each other, it is not sufficient
to lower lipid levels by statins, and composite therapies
are needed to prevent the progression of CVD in PD pa-
tients. It has been reported that icodextrin improves PD
patient survival [33,34]. This study suggests that icodex-
trin improves the lipid profile in PD patients in a manner
different from statins. From these results, icodextrin is acandidate therapy for the composite anti-CVD therapies
after statins.
In this study, although conventional measurement of
cholesterol levels in lipoprotein classes could not reveal
the differences in lipid profiles between the icodextrin
and control groups, measurement of cholesterol levels in
lipoprotein fractions could detect a difference. There has
been increasing evidence of the importance of more de-
tailed lipid measurements. An observational study of
hemodialysis patients showed that total cholesterol, LDL-
C, and HDL-C levels are not associated with mortality,
but that the smaller size of LDL particles is related to the
poor prognosis of patients [35]. These results suggest a
hypothesis that cholesterol levels in lipoprotein fractions
predict more precisely a patient’s prognosis than those in
lipoprotein classes. However, the role of detailed lipopro-
tein fractions in atherosclerosis is unclear in PD patients.
This is a rationale to study the lipoprotein fractions in PD
patients and whether lipid-lowering therapies in lipopro-
tein fractions improve the survival of PD patients with
interventional icodextrin treatment.
This study has several limitations. First, as with any
cross-sectional study, we were unable to examine the lon-
gitudinal changes in laboratory findings over time. Second,
this study had only forty-nine patients. The statistical
power of this study may not be sufficient for detecting the
relationship between icodextrin use and lipoprotein frac-
tions. Third, geographical and selection bias may have
been included in this study. Fourth, we did not investigate
the calorie intake such as diet and glucose load of PD so-
lution. We were unable to adjust for the effects of calorie
intake on dyslipidemia. Fifth, the lipid profiles are affected
time-dependently by using the PD solution with icodex-
trin. A longitudinal study is needed to reveal the time-
dependent effect of icodextrin on lipid profile. In this
study, PD vintage was equal to the period of use of a PD
solution with or without icodextrin. Sixth, there is a possi-
bility that the absorbed icodextrin in samples may have
caused measurement errors in serum glucose levels. How-
ever, because blood samples were obtained from every pa-
tient with an overnight dwell of PD solution containing
2.5% dextrose, and the glucose levels were not used in the
regression models, the effect of icodextrin on the errors in
serum glucose levels was decreased. Seventh, because
most of the patients showed anuria, we were unable to
precisely evaluate their urine volume.
Conclusions
Among PD patients, the relationships between icodex-
trin use and cholesterol proportions in small and very
small LDLs and HDLs were observed by HPGPC. These
relationships were independent of statin use. Icodextrin
may improve atherogenic lipid profiles in fraction level
in a manner different from statin in PD patients.
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